Keynote-905/Ev-303: Perioperative Pembrolizumab Or Pembrolizumab Plus Enfortumab Vedotin (Ev) And Cystectomy Compared To Cystectomy Alone In Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer (Mibc).
JOURNAL OF CLINICAL ONCOLOGY（2021）
Abstract
TPS507Background: Patients with MIBC who are ineligible for neoadjuvant cisplatin-based chemotherapy receive the standard-of-care treatment of radical cystectomy (RC) and pelvic lymph node dissecti...
MoreTranslated text
Key words
perioperative pembrolizumab,bladder cancer,cystectomy,cisplatin-ineligible,muscle-invasive
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined